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funBACKGROUND The long-term outcome of atrial ﬁbrillation (AF) ablation demonstrates attrition. This outcome may be
due to failure to attenuate the progressive substrate promoted by cardiovascular risk factors.
OBJECTIVES The goal of this study was to evaluate the impact of risk factor and weight management on AF ablation
outcomes.
METHODS Of 281 consecutive patients undergoing AF ablation, 149 with a body mass index $27 kg/m2 and $1 cardiac
risk factor were offered risk factor management (RFM) according to American Heart Association/American College of
Cardiology guidelines. After AF ablation, all 61 patients who opted for RFM and 88 control subjects were assessed every
3 to 6 months by clinic review and 7-day Holter monitoring. Changes in the Atrial Fibrillation Severity Scale scores
were determined.
RESULTS There were no differences in baseline characteristics, number of procedures, or follow-up duration between
the groups (p ¼ NS). RFM resulted in greater reductions in weight (p ¼ 0.002) and blood pressure (p ¼ 0.006), and
better glycemic control (p ¼ 0.001) and lipid proﬁles (p ¼ 0.01). At follow-up, AF frequency, duration, symptoms, and
symptom severity decreased more in the RFM group compared with the control group (all p < 0.001). Single-procedure
drug-unassisted arrhythmia-free survival was greater in RFM patients compared with control subjects (p < 0.001).
Multiple-procedure arrhythmia-free survival was markedly better in RFM patients compared with control subjects
(p < 0.001), with 16% and 42.4%, respectively, using antiarrhythmic drugs (p ¼ 0.004). On multivariate analysis, type
of AF (p < 0.001) and RFM (hazard ratio 4.8 [95% conﬁdence interval: 2.04 to 11.4]; p < 0.001) were independent
predictors of arrhythmia-free survival.
CONCLUSIONS Aggressive RFM improved the long-term success of AF ablation. This study underscores the importance
of therapy directed at the primary promoters of the AF substrate to facilitate rhythm control strategies. (J Am Coll
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AND ACRONYM S
AF = atrial ﬁbrillation
AFSS = Atrial Fibrillation
Severity Scale
AHI = apnea–hypopnea index
BMI = body mass index
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2223A trial ﬁbrillation (AF) affectsw2.7 million peo-ple in the United States alone, and its preva-lence is expected to rise to 15.9 million by
2050, with a signiﬁcant impact on health care (1–3).
Although population aging is regarded as an important
contributor, several risk factors such as hypertension,
diabetes mellitus (DM), obesity, and obstructive sleep
apnea (OSA) have been linked as promoters of AF (4–7).SEE PAGE 2232
BP = blood pressure
CI = conﬁdence interval
CPAP = continuous positive
airway pressure
DM = diabetes mellitus
HR = hazard ratio
LA = left atrial
LV = left ventricular
OSA = obstructive sleep apneaCatheter ablation of AF has evolved as an effective
therapy for drug-refractory symptomatic AF (8).
Studies have demonstrated the advantage of catheter
ablation over pharmacological methods of rhythm
control (9–12). However, reports of long-term out-
comes of AF ablation demonstrate attrition in success
with time (13–17). Studies have associated some cardiac
risk factors with more frequent recurrence of AF (18–
20). We hypothesized that the attrition in the success
of AF ablation is due to progression of the disease
process that promoted the development of AF. The
goal of the present study was to evaluate the impact of
aggressive cardiac risk factors and weight manage-
ment on outcomes of catheter ablation.
METHODS
STUDY POPULATION. The study comprised consecu-
tive patients with a body mass index (BMI) $27 kg/m2
and $1 risk factor (hypertension, glucose intolerance/
DM, hyperlipidemia, OSA, smoking, or alcohol excess)
undergoing initial catheter ablation for symptomatic
AF despite the use of antiarrhythmic medication.
All patients provided written informed consent for
the ablation procedure and collection of their clinical
data. The Human Research Ethics Committee of the
Royal Adelaide Hospital and University of Adelaide
approved the study protocol.
STUDY PROTOCOL. All suitable patients were
offered risk factor management (RFM) in a dedicatedScholarship from the Lion’s Medical Research Foundation and an Australian
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assessment. Patients who accepted this
strategy formed the intervention group (RFM
group), and those who declined formed the
control group. Only patients with ongoing
signiﬁcant symptoms, despite the use of
antiarrhythmic medications and RFM, un-
derwent AF ablation. Exclusion criteria were:
history of myocardial infarction or cardiac
surgery in the previous 12 months; previous
AF ablation; active malignancy; autoimmune
or systemic inﬂammatory disease; severe
renal or hepatic failure; and <12 months’
follow-up after their procedure.
RFM GROUP. Patients participating in RFM
attended a physician-directed RFM clinic (in
addition to their arrhythmia follow-up) every 3
months andweremanaged according toAmericanCollege
of Cardiology/American Heart Association guidelines (21).
Blood pressure contro l . Blood pressure (BP) was
measured thrice daily by using a home-based auto-
mated monitor and an appropriate-sized cuff. In
addition, exercise stress testing was performed to
determine the presence of exercise-induced hyper-
tension, with BP >200/100 mm Hg considered as
evidence to optimize therapy. Lifestyle advice
constituted dietary salt restriction. Pharmacotherapy
was initiated by using renin-angiotensin-aldosterone
system antagonists, with other agents used when
necessary to achieve a target BP of <130/80 mm Hg at
least 80% of the time. These were corroborated by
in-ofﬁce and 24-h ambulatory BP measurements, as
required. Echocardiography was monitored to ensure
resolution of left ventricular (LV) hypertrophy.
Weight management . A structured motivational
and goal-directed program using face-to-face
counseling was used for weight reduction. Patients
were encouraged to utilize support counseling and
schedule more frequent reviews, as required. Initial
weight reduction was attempted by using a mealPostgraduate Award from the University of Adelaide.
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Consecutive patients undergoing first
AF ablation
n=281
Patients with BMI ≥ 27 + 1 or more
cardiac risk factors
n=165
Aggressive risk factor management
offered
Accepted: RF management
n=69
Refused: Control
n=96
Lost to follow up n=6
Excluded n=2
Lost to follow up n=7
Excluded n=1
RF management group
n=61
Control group
n=88
FIGURE 1 Patient Selection
Flow diagram of patient recruitment and attrition. Of 165 patients (69 in the risk factor
[RF] management group and 96 in the control group), 16 were excluded from the analysis
due to lack of regular follow-up in 13 from other states (7 RF management and 6 control)
or systemic illness in 3 (1 with malignancy and 2 with systemic inﬂammatory diseases).
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index.
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2224plan and behavior modiﬁcation. Participants were
required to maintain a diet and physical activity
diary. Meals consisted of high-protein and low gly-
cemic index, calorie-controlled foods. If patients
lost <3% of weight after 3 months, they were then
prescribed very low calorie meal replacement sachets
(Prima Health Solutions, Sydney, Australia, or Nestlé
Health Science, Sydney, Australia) for 1 to 2 meals per
day. The initial goal was to reduce body weight by
10%. After patients achieved the initial goal, meal
replacement was substituted with high-protein and
low glycemic index, calorie-controlled foods to ach-
ieve a target BMI of #25 kg/m2. Low-intensity exer-
cise was prescribed initially for 20 min thrice weekly,
increasing to at least 200 min of moderate-intensity
activity per week.
L ip id management . Lipids were initially managed
with lifestyle measures; if patients were un-
able to achieve low-density lipoprotein cholesterol
levels <100 mg/dl after 3 months, use of a hydroxy-
methylglutaryl coenzyme A reductase inhibitor was
then initiated. Fibrates were used for isolated
hypertriglyceridemia (triglycerides >500 mg/dl) or
added to statin therapy if triglyceride levels were
>200 mg/dl and non–high-density lipoprotein
cholesterol levels were >130 mg/dl.Glycemic contro l . A glucose tolerance test was
performed if fasting glucose levels were 100 to 125
mg/dl. Impaired glucose tolerance or DM was initially
managed with lifestyle measures. If patients were
unable to maintain glycosylated hemoglobin (HbA1c)
levels #6.5% after 3 months, metformin was started.
Patients in both groups with suboptimal glycemic
control (HbA1c >7%) were referred to a specialized
diabetes clinic.
Sleep-disordered breathing management. In-laboratory
overnight polysomnography was scored by qualiﬁed
sleep technicians and reviewed with follow-up by
a sleep physician. The scoring was according to
the American Academy of Sleep Medicine alternate
polysomnography scoring criteria (22). Patients were
offered therapy if the apnea–hypopnea index (AHI)
was $30/h or if it was >20/h with resistant hyper-
tension or problematic daytime sleepiness. Treat-
ment included positional therapy and continuous
positive airway pressure (CPAP).
Smoking and a lcohol . The “5As” (ask, advise,
assess, assist, and arrange follow-up) structured
smoking cessation framework was adopted. Smokers
were offered behavioral support through a multidis-
ciplinary clinic with the aim of smoking cessation.
Written and verbal counseling was provided with
regular supportive follow-up for alcohol reduction
to #30 g/week.
CONTROL GROUP. The control group was given
information on management of risk factors. However,
they continued RFM under the direction of their
treating physician.
CATHETER ABLATION. The ablation procedure was
performed with the operator blinded to the patient’s
study group. The ablation technique used at our
institution has been described previously (23) and
included wide-encircling pulmonary vein ablation
with an endpoint of electrical isolation (pulmonary
vein isolation) in all patients. Further substrate
modiﬁcation was performed for patients with AF
episodes $48 h or if the largest left atrial (LA)
dimension exceeded 57 mm. This included linear
ablation (rooﬂine and/or mitral isthmus) with an
endpoint of bidirectional block and/or electrogram-
guided ablation of fractionated sites.
If patients developed recurrent arrhythmia after
the blanking period (3 months), repeat ablation was
offered. Individual operators decided on the extent of
additional ablation undertaken beyond reisolation of
the pulmonary veins.
FOLLOW-UP. Physicians blinded to the patient’s
study group assessed patients for arrhythmia recur-
rence. Reviews were every 3 months for the ﬁrst year
TABLE 1 Baseline Characteristics
Control Group
(n ¼ 88)
RFM Group
(n ¼ 61) p Value
Age, yrs 57.2  9.9 58.4  10.8 0.5
Male 61 (69.3) 34 (56) 0.1
Anthropometric measures
Weight, kg 96.6  16.8 100.7  17.6 0.2
BMI, kg/m2 32.1  4.7 33.5  4.6 0.1
AF type
Paroxysmal 49 (56) 40 (65) 0.2
Nonparoxysmal 39 (44) 21 (35)
Metabolic risk factors
Hypertension 73 (83) 53 (87) 0.5
Diabetes mellitus 17 (19) 9 (15) 0.5
Hyperlipidemia 47 (53) 39 (64) 0.2
Coronary artery disease 10 (11) 10 (16) 0.4
AHI >30 55 (62) 32 (53) 0.2
Alcohol excess (>30 g/week) 24 (27) 11 (18) 0.2
Smoker 31 (35) 20 (33) 0.8
Medication use
No. of antiarrhythmic agents 1.0  0.2 1.1  0.3 0.1
No. of antihypertensive
agents
1.6  1.2 1.5  1.1 0.4
Echocardiographic measures
LA volume index, ml/m2 42.4  10.4 42.5  12 0.9
LV septum, mm 11.0  2 12.0  2 0.1
LVIDd, cm 5.1  0.7 5.3  0.5 0.2
LVEF, % 60  10.1 61.1  8 0.5
Atrial Fibrillation Severity Scale
Frequency (1–10) 6.6  1.1 6.8  1.2 0.5
Duration (1–10) 6.7  1.3 6.4  1.6 0.3
Severity (1–10) 6.9  1.3 6.6  1.5 0.2
Symptom (0–35) 23.1  3.7 22  5.2 0.1
Global well-being (1–10) 2.5  0.9 2.4  0.9 0.4
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; AHI ¼ apnea–hypopnea index; BMI ¼ body mass index;
LA ¼ left atrial; LV ¼ ventricular; LVEF ¼ left ventricular ejection fraction; LVIDd¼
left ventricular internal dimension in diastole; RFM ¼ risk factor management.
J A C C V O L . 6 4 , N O . 2 1 , 2 0 1 4 Pathak et al.
D E C E M B E R 2 , 2 0 1 4 : 2 2 2 2 – 3 1 Risk Factor Reduction and AF Ablation
2225and then every 6 months thereafter. At each review,
AF recurrence was ascertained from patients’ symp-
toms, electrocardiograms, and ambulatory 7-day
monitoring. Two independent observers blinded to
patient group analyzed the ambulatory recordings. In
the absence of any arrhythmia, antiarrhythmic drugs
were stopped at 4 to 6 weeks. No patient continued
on amiodarone after ablation. All patients underwent
anticoagulation by using warfarin for $3 months
after ablation.
Procedural success was determined as the absence
of any atrial arrhythmia $30 s after a 3-month
blanking period.
AF SYMPTOM BURDEN. AF symptom burden and
severity were quantiﬁed by using the validated Atrial
Fibrillation Severity Scale (AFSS, University of
Toronto, Toronto, Ontario, Canada) (24). The AFSS is
used to quantify 3 domains of AF-related symptoms:
frequency, duration, and severity. A symptom sub-
scale was also determined. The AFSS questionnaire
was administered at baseline and at follow-up after
ablation.
CARDIAC STRUCTURE. Transthoracic echocardiog-
raphy was performed at baseline and yearly by
using a 3.5-MHz probe. Measurements were per-
formed according to American Society of Echo-
cardiography guidelines by an operator blinded to the
study group.
STATISTICAL ANALYSIS. Categorical variables are
represented by frequencies and percentages, and
continuous variables are summarized by mean  SD.
Repeated measure analysis of variance was used to
assess the interaction between the groups over time.
The signiﬁcance of the interaction in the analysis of
variance was used to assess these changes. Compari-
sons of variables for both the control and RFM groups
were performed by using paired samples Student t
tests. For nominal variables, such as diabetes and
sleep apnea (AHI >30), changes were only assessed
for patients who were positive at baseline. The
change in the status at ﬁnal follow-up was compared
between the 2 groups by using chi-square tests. The
Kaplan-Meier product-limit method was used to es-
timate the time to recurrence and event-free sur-
vival curves after the last ablation procedure.
Requirement for a repeat procedure was considered
an endpoint. Predictors of recurrent AF were
assessed in Cox regression models after verifying
proportionality assumptions. Candidate variables
with p < 0.1 in univariate analyses were considered
in multivariate stepwise regression models. Two-
tailed p values <0.05 were considered statistically
signiﬁcant. Statistical analysis was performed byusing SPSS version 21.0 (IBM SPSS Statistics, IBM
Corporation, Armonk, New York).
RESULTS
BASELINE CHARACTERISTICS. Of 281 consecutive
patients referred for catheter ablation of symptomatic
AF, 165 had both BMI $27 kg/m2 and $1 risk factor. Of
these, 3 patients were excluded on the basis of pre-
deﬁned exclusions (1 with terminal cancer and 2 with
systemic inﬂammatory conditions) and an additional
13 on the basis of the lack of regular follow-up (from
other states). The ﬁnal cohort included 149 patients:
61 RFM patients and 88 control subjects (Figure 1).
Mean follow-up in the RFM and control groups were
41.6  12.5 months and 42.1  14.2 months, respec-
tively (p ¼ 0.8). Mean duration before the procedure
was 9.8  7.1 months in the RFM group and
TABLE 2 Risk Factor, Echocardiographic, and AF Severity Changes
Control Group
(n ¼ 88)
p Value*
RFM Group
(n ¼ 61)
p Value* p Value†Baseline Follow-Up‡ Baseline Follow-Up‡
Risk factors
Weight, kg 96.6  16.8 95.8  17.6 0.13 100.7  17.6 87.5  14.9 <0.001 0.002
BMI, kg/m2 32.1  4.7 31.8  4.9 0.12 33.5  4.6 29.1  3.9 <0.001 <0.0011
Mean SBP, mm Hg 158.7  21.3 138.2  18.0 <0.001 160.8  20.3 126.8  12.8 <0.001 0.006
DM with HbA1c $7%, n 17 5 9 0 0.001
No. with AHI >30 54 46 32 16 <0.001
Medication use
No. of antiarrhythmic agents 1.0  0.2 0.7  0.7 <0.001 1.1  0.3 0.3  0.6 <0.001 <0.001
No. of antihypertensive agents 1.6  1.2 1.9  1.3 0.2 1.5  1.1 1.2  0.9 0.04 <0.001
Echocardiographic measures
LA volume index, ml/m2 42.4  10.4 39.5  12.1 0.07 42.5  12 30.4  8.3 <0.001 0.001
LV septum, mm 11.0  2.0 10.9  0.19 0.047 12.0  2.0 9.6  0.17 <0.001 <0.001
LVIDd, cm 5.1  0.7 5.1  0.6 0.204 5.3  0.5 4.9  0.6 <0.001 0.047
LVEF, % 60  10.1 61.1  8 0.538 61.3  10 62.6  5.5 0.524 0.971
Atrial Fibrillation Severity Score
AF frequency (1–10) 6.6  1.1 3.2  1.1 <0.001 6.8  1.2 2.0  0.9 <0.001 <0.001
AF duration (1.25–10) 6.7  1.3 3.3  1.3 <0.001 6.4  1.6 2.1  0.9 <0.001 0.001
AF episode severity (1–10) 6.9  1.3 5.2  1.9 <0.001 6.6  1.5 3.3  1.5 <0.001 <0.001
AF symptom subscale (0–35) 23.1  3.7 13.3  6.2 <0.001 22  5.2 7.1  4.6 <0.001 <0.001
Global well-being (1–10) 2.5  0.9 5.7  2.0 <0.001 2.4  0.9 7.6  1.7 <0.001 <0.001
Values are mean  SD or n. *The p value is for within-group differences (baseline to follow-up). †The p value is for between-group differences over time
(group–time interaction). ‡Median follow-up: 42.8 months for the RFM group and 42.4 months for the control group.
DM ¼ diabetes mellitus; HbA1c ¼ glycosylated hemoglobin; SBP ¼ systolic blood pressure; other abbreviations as in Table 1.
TABLE 3 Procedure Details
Control Group RFM Group p Value
First procedure 88 61
PV isolation 88 (100) 61 (100) 0.2
Line ablation 60 (68) 40 (66) 0.7
CAFE 23 (27.1) 21 (34) 0.3
Second procedure 46 28
PV consolidative ablation 46 (52) 28 (46) 0.08
Line ablation 36 (41) 21 (34) 0.3
CAFE 15 (17) 6 (10) 0.4
Third procedure 13 6
PV consolidative ablation 13 (28) 6 (21) 0.6
Line ablation 6 (6.8) 5 (8.2) 0.5
CAFE 0 1 0.8
Values are n or n (%).
CAFE ¼ complex atrial fractionated electrograms; PV ¼ pulmonary vein;
RFM ¼ risk factor management.
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222610.2  9.2 months in the control group (p ¼ 0.8).
Baseline characteristics were similar in the 2 groups
(Table 1).
RISK FACTOR MODIFICATION. Table 2 shows the
impact of RFM on various cardiac risk factors.
For BP control, there was a greater decline in
systolic BP in RFM patients compared with control
subjects (34.1  7.5 mm Hg vs. 20.6  3.2 mm Hg;
p ¼ 0.003). The number of antihypertensive agents
used for BP control decreased with RFM (1.5  1.1 to
1.2  0.9; p ¼ 0.04) and increased in the control group
(1.6  1.2 to 1.9  1.3; p ¼ 0.2).
Weight and BMI decreased in both groups but
signiﬁcantly more in the RFM group compared with
the control group (–13.2  5.4 kg vs. –1.5  5.1 kg;
p ¼ 0.002) (Table 2).
At baseline, 64% of RFM patients and 53% of
control subjects had dyslipidemia (p ¼ 0.2). With diet
and lifestyle modiﬁcation, low-density lipoprotein
cholesterol and non–high-density lipoprotein choles-
terol levels were well controlled in 46.2% of RFM
patients and 17% of control subjects (p ¼ 0.01). Drug
therapy was required in 43.6% of the RFM group and
68.1% of the control group (p ¼ 0.01). At ﬁnal follow-
up, 10.2% (n ¼ 4) of RFM patients and 15% (n ¼ 7) of
control subjects still had dyslipidemia.At baseline, 15% of RFM patients and 19% of
control subjects had a history of DM (p ¼ 0.5). An
additional 13% of RFM patients and 10% of control
subjects were found to have impaired glucose toler-
ance. At the ﬁnal follow-up, DM patients in the RFM
group had signiﬁcantly better glycemic control
compared with control subjects: HbA1c levels <7% in
100% versus 29%, respectively (p ¼ 0.001).
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2227At baseline, 52% of RFM patients and 61% of control
subjects had severe OSA (AHI$30; p¼0.2). Of these, 16
(50%) RFM patients had an AHI <15, which we regar-
ded as mild or no OSA when retested at follow-up,
compared with 8 (15%) control subjects (p < 0.001).
Of patients requiring CPAP, compliance with CPAP use
was signiﬁcantly higher in RFM patients compared
with control subjects (77% vs. 32%; p ¼ 0.001).8 Group
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22281.5  0.7 [p ¼ 0.3]). Table 3 provides procedural
details for each group.
CARDIAC STRUCTURE. Table 2 shows the effect of
RFM on cardiac structure. LA volume indexed for
body surface area decreased with RFM from
42.5  12.0 ml/m2 to 30.4  8.3 ml/m2 (p < 0.001) and
in control subjects from 42.4  10.4 ml/m2 to
39.5  12.1 ml/m2 (p ¼ 0.07); this reduction was
signiﬁcantly greater with RFM patients compared with
control subjects (p ¼ 0.001). Interventricular septum
thickness decreased with RFM from 11.6  1.7 mm to
9.6  1.7 mm (p < 0.001) and in control subjects from
11.3  1.6 mm to 10.9  1.9 mm (p ¼ 0.04). There was a
greater reduction in the RFM patients compared with
the control subjects (p < 0.001).
ATRIAL FIBRILLATION. Symptom burden . At base-
line, both groups had comparable and high AFSS
subscale scores (Table 2). Figure 2 shows changes from
baseline to ﬁnal follow-up for the AFSS subscale
pertaining to total AF burden and symptom severity.
AF frequency, duration, symptoms, and symptom
severity were less at ﬁnal follow-up in both groups,
with a signiﬁcantly greater reduction seen with the
RFM group (p < 0.001). The global well-being score0.0
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FIGURE 3 Outcomes of AF Ablation
Kaplan-Meier curves for single-procedure, drug-free, AF-free survival (l
(right). Curves for 2 years are provided, after which <20% of patients c
procedure using a 3-month blanking period. RFM ¼ risk factor managemimproved by >2-fold after ablation, with the RFM
group improving from 2.4  0.9 to 7.6  1.7 (p < 0.001)
and the control group improving from 2.5  0.9 to
5.7  2.0 (p < 0.001). However, improvement was
markedly better with RFM patients than with control
subjects (p < 0.001).
Single-procedure arrhythmia-free survival. Figure 3
demonstrates single-procedure outcomes. At ﬁnal
follow-up, 32.9% of RFM patients versus 9.7% of
control subjects (p < 0.001) remained free from
arrhythmia. After a single procedure, univariate pre-
dictors of AF recurrence were control group (hazard
ratio [HR]: 2.6 [95% conﬁdence interval (CI): 1.7 to 4.0];
p < 0.001) and type of AF (nonparoxysmal AF: HR: 1.8
[95% CI: 1.2 to 2.7]; p ¼ 0.004). Both factors remained
independent predictors of recurrent AF inmultivariate
analyses: control group, HR: 2.3 (95% CI: 1.5 to 3.6;
p < 0.001) and nonparoxysmal AF, HR: 1.7 (95% CI:
1.1 to 2.5; p ¼ 0.01). Differences in outcomes on the
basis of AF type are shown in Online Figure 1.
Multiple interventions arrhythmia-free survival.
Figure 3 demonstrates arrhythmia-free survival after
multiple procedures, with signiﬁcant attrition in
control subjects compared with RFM patients. At ﬁnal0.0
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eft) and for total AF-free survival (multiple procedures  drugs)
ompleted follow-up. Note that data are provided after the last
ent; other abbreviation as in Figure 1.
ATRIAL FIBRILLATION (AF) PATHOGENESIS INTERVENTION
Risk factor contributors:
Hypertension; diabetes mellitus; obesity;
obstructive sleep apnea (OSA); 
smoking; and alcohol use
Atrial remodeling/substrate for AF:
Structural, electrical, autonomic
Pathak, R.K. et al. J Am Coll Cardiol. 2014; 64(21):2222–31.
Risk Factor Management (RFM):
Blood pressure; weight; 
lipid; glycemic; OSA;
smoking; and alcohol
Continued Risk Factor 
Management
Substrate modification
Substrate modificationSubstrate progression
Atrial fibrillation
Atrial fibrillation
catheter ablation
Reduced AF burden
Reduced AF recurrenceAblation outcome
CENTRAL ILLUSTRATION Impact of Risk Factor and Weight Management on
AF Ablation Outcomes
The schematic demonstrates the natural progression of the atrial ﬁbrillation (AF) substrate
and its impact on the maintenance of sinus rhythm (blue). Risk factor management has
been demonstrated to reduce the burden of AF and also improve the outcomes of catheter
ablation (salmon).
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2229follow-up, arrhythmia-free survival rates after the
last catheter ablation procedure were 87% with RFM
compared with 17.8% for the control group
(p < 0.001). Univariate predictors of AF recurrence
after multiple procedures were: control group (HR:
6.2 [95% CI: 2.6 to 14.5]; p < 0.001); type of AF
(nonparoxysmal AF: HR: 3.3 [95% CI: 1.8 to 5.9]; p <
0.001); and poor BP control, evidenced by the number
of antihypertensive medications (HR: 1.3 [95% CI: 1.03
to 1.64]; p ¼ 0.02). Patient group (HR: 4.8 [95% CI:
2.04 to 11.4]; p < 0.001) remained the most signiﬁcant
predictor of recurrent AF in multivariate analyses.
Online Figure 1 displays the differences in outcome
on the basis of AF type.
DISCUSSION
This study found that in patients with highly symp-
tomatic AF undergoing ablation, a structured
physician-directed risk factor and weight manage-
ment program resulted in signiﬁcant improvement
in the long-term outcomes. These effects were asso-
ciated with structural remodeling, with signiﬁcant
improvement in LA volumes and LV hypertrophy.
The ﬁndings emphasize the importance of treating
the underlying causes of AF to achieve rhythm con-
trol and maintenance of sinus rhythm.
Catheter ablation is an effective therapy for rhythm
control in patients with drug-refractory or intolerant
AF. Despite recent advances in ablative techniques,
long-term outcomes post-ablation have not improved
proportionately, especially in those with more
persistent forms of the arrhythmia (25). Updates
from several centers conﬁrm the need for multiple
procedures, which, in general, have occurred early
(13,14,26) and are related to incomplete ablation
during previous efforts with residual pulmonary vein
conduction (27,28). More concerning is that, despite
further ablation and a period without arrhythmia,
progressive attrition in success is observed with time
(13,14,18). This late recurrence was proposed to also
be due to persistent pulmonary vein conduction
(27,28). However, it seems unusual that recovery
of pulmonary vein conduction, which would be
expected to occur early, would contribute to delayed
recurrence of arrhythmia. Several single-center ex-
periences identiﬁed a variety of cardiac risk factors
that were more frequently present in patients with
late recurrence of AF (19,20,29,30).
Cardiac risk factors such as hypertension, DM,
obesity, and OSA have been independently shown to
increase the incidence of AF (4–6,31). Importantly,
these cardiac risk factors are associated with struc-
tural and electrical remodeling of the atria that formsthe substrate leading to AF development and pro-
gression (32–34). Indeed, even in the absence of
known risk factors, atrial changes consistent with
the AF substrate have been observed in “lone AF”
patients (23). Several studies allude to further evi-
dence of the importance of an underlying substrate to
the progression of AF. It was postulated that early
cardioversion would prevent remodeling due to AF
and allow “sinus rhythm to beget sinus rhythm”;
however, restoration of sinus rhythm reversed elec-
trical remodeling but did not affect sinus rhythm
maintenance (35). Finally, in a recent study, a pro-
gressive atrial substrate was observed, even after
successful catheter ablation of AF (26). These ﬁndings
argue in favor of an underlying atrial substrate
responsible for AF, which is promoted by inade-
quately treated or unrecognized risk factors.
Upstream therapy has been demonstrated to
reduce AF. Antihypertensive therapy reduces LA size
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Recurrence of AF during long-term follow-up after
catheter-based ablation is due to progression of un-
derlying atrial pathology.
COMPETENCY IN PATIENT CARE: Control of risk
factors (including excessive body weight) is an
important component of a rhythm control strategy for
patients with AF.
TRANSLATIONAL OUTLOOK: Further studies are
needed to clarify the mechanisms by which obesity is
related to the progression of the atrial pathology
associated with recurrent or refractory AF.
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2230and LV hypertrophy, leading to a lower risk of AF (36).
Angiotensin receptor blockade in conjunction with
cardioversion reduces the recurrence of AF (37). In
mitral stenosis, treatment of the primary cause
reversed the abnormal atrial substrate (38). A recent
study observed that weight and cardiometabolic RFM
in overweight individuals with AF resulted in a
reduction of the AF symptom burden (39). In the
setting of AF ablation, emerging data showed that
CPAP for OSA was associated with higher ablation
success (29).
The present study extends these observations by
demonstrating markedly improved outcomes of
maintaining sinus rhythm by addressing each of the
risk factors that potentially contributed to AF devel-
opment and, therefore, to the underlying atrial
substrate. The results are so striking that concurrent
risk factor treatment seems an essential component
of strategies for rhythm control in patients with AF
(Central Illustration).
STUDY LIMITATIONS. This study was a single-center,
observational study and requires conﬁrmation in a
randomized controlled trial to minimize the potential
for selection bias and better control of confounders.
Finally, we targeted each risk factor, treating to
recommended targets. As a result, this study does not
provide insight into the relative contribution of each
risk factor or variable treatment targets.
CONCLUSIONS
RFM signiﬁcantly improved the outcomes of AF
ablation by reducing AF burden and severity inconjunction with favorable changes in cardiac
remodeling in these study patients. The ﬁndings
underscore the importance of therapy directed at
the primary promoters of the AF substrate to
facilitate a rhythm control strategy in patients with
AF.
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